{
    "clinical_study": {
        "@rank": "6439", 
        "acronym": "H2H", 
        "arm_group": {
            "arm_group_label": "HO/03/03 10-40 micro gram", 
            "arm_group_type": "Experimental", 
            "description": "Topically treatment with HO/03/03 10-40\u00b5g once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10\u00b5g at a dose of 1-4 vials (i.e. 10-40 \u00b5g/administration) daily depending on their wound size."
        }, 
        "brief_summary": {
            "textblock": "This multicenter, prospective, open-label, outpatient study will assess the safety and\n      efficacy of HO/03/03 10\u00b5g applied topically once daily for up to 24 weeks in up to 100\n      subjects with Hard to Heal documented chronic wounds of various etiologies (pressure ulcers,\n       diabetic ulcers, post operational wounds surgical incisions ulcers of rheumatoid arthritis\n      and trauma wounds) of at least 4 weeks documentation."
        }, 
        "brief_title": "Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Hard to Heal Wounds", 
        "detailed_description": {
            "textblock": "All subjects with a wound size of up to 56.25 cm2 (inclusive) will be administered 1 vial of\n      10 ml HO/03/03 10\u03bcg per administration. For each increase in wound size of up to 56.25 cm2\n      an additional vial of HO/03/03 10 \u03bcg will be added up to a maximal wound size area of 225\n      cm2 (will be measured by HealOr central reviewer) utilizing 40\u00b5g (4 vials) per\n      administration. 15 min post treatment wounds will be dressed according to standard of care."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years old and above.\n\n          -  Chronic wounds that have < 30% change in area from Screening\n\n          -  Have single / multiple wounds;\n\n          -  Have a Hard-to-Heal wound(s) of various etiologies\n\n        Exclusion Criteria:\n\n          -  Have a documented medical history of a significant cardiac, pulmonary,\n             gastrointestinal, endocrine (other than Diabetes Mellitus type 1 or 2), hepatic or\n             per the physician's discretion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772303", 
            "org_study_id": "HO-H2H-01-2011"
        }, 
        "intervention": {
            "arm_group_label": "HO/03/03 10-40 micro gram", 
            "description": "HO/03/03 10-40\u00b5g once daily (Topically) for up to 24 weeks.", 
            "intervention_name": "HO/03/03 10-40 \u00b5g", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pressure Ulcers, diabetic Ulcers, post operational wounds", 
        "lastchanged_date": "April 3, 2013", 
        "location": {
            "contact": {
                "email": "raba_m@mac.org.il", 
                "last_name": "Michal Raba", 
                "phone": "+972-50-2400362"
            }, 
            "contact_backup": {
                "email": "dr.kaufmanh1@gmail.com", 
                "last_name": "Hanna Kaufman, MD", 
                "phone": "+972-50-9063142"
            }, 
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel"
                }, 
                "name": "Maccabi Health Services, Wound Clinic"
            }, 
            "investigator": {
                "last_name": "Hanna Kaufman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Prospective, Multicenter Study to Assess the Safety and Efficacy of HO/03/03 10-40 Micro Gram (Wound Size Dependence) Applied Topically for up to 24 Weeks in Subjects With Various Etiologies of Hard-to-Heal Wounds", 
        "overall_contact": {
            "email": "yair@healor.com", 
            "last_name": "Yair Alegranti", 
            "phone": "+972-54-3161581"
        }, 
        "overall_contact_backup": {
            "email": "kira@healor.com", 
            "last_name": "Kira Olshvang", 
            "phone": "+972-54-3161572"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "\"Institutional Review Board:Israel\"", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "1.\t75% wound closure by or on study week 24 (Time to Event Analysis of incidence and time to 75% wound closure).", 
            "measure": "Time to Heal", 
            "safety_issue": "No", 
            "time_frame": "up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772303"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "1. Complete wound closure by or on week 24 (Time to Event Analysis of incidence and time to 100% wound closure).", 
            "measure": "Wound closure", 
            "safety_issue": "No", 
            "time_frame": "up to 24 weeks"
        }, 
        "source": "HealOr", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "HealOr", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}